Multidisciplinary Management of COVID-Associated Mucormycosis Syndemic in India

Edara V-V, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv [Internet]. 2021 May 10 [cited 2021 Jun 2]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132229/ Prakash H, Chakrabarti A (2021) Epidemiology of mucormycosis in India. Microorganisms 9(3):523 Sharma NC. 28,252 cases of black fungus detected so far, says Centre [Internet]. mint. 2021 [cited 2021 Aug 30]. Available from: https://www.livemint.com/news/india/28-states-report-over-28-252-cases-of-mucormycosis-11623068251495.html Frank GS, Smith JM, Davies BW, Mirsky DM, Hink EM, Durairaj VD (2015) Ophthalmic manifestations and outcomes after cavernous sinus thrombosis in children. J Am Assoc Pediatr Ophthalmol Strabismus 19(4):358–362 Hartnett KP, Jackson BR, Perkins KM, Glowicz J, Kerins JL, Black SR et al (2019) A guide to investigating suspected outbreaks of mucormycosis in healthcare. J Fungi 5(3):69 Lass-Flörl C (2017) Current challenges in the diagnosis of fungal infections. In: Lion T (eds) Human Fungal Pathogen Identification: Methods and Protocols [Internet]. Springer, New York, [cited 2021 Jun 6]. p 3–15. (Methods in Molecular Biology). Available from: https://doi.org/10.1007/978-1-4939-6515-1_1 Shekar V, Sikander J, Rangdhol V, Naidu M (2015) Facial nerve paralysis: a case report of rare complication in uncontrolled diabetic patient with mucormycosis. J Nat Sci Biol Med 6(1):226–228 Gelston CD (2007) Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole. Arch Ophthalmol 125(6):848 Jain S, Kumar S, Kaushal A (2011) Rhinocerebral mucormycosis with isolated sixth nerve palsy in an immunocompetent patient. Med J Malaysia 66(4):376–378 Gillespie MB, O’Malley BW (2000) An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 33(2):323–334 Gravesen S (1979) Fungi as a Cause of Allergic Disease. Allergy 34(3):135–154 Hosseini SMS, Borghei P (2005) Rhinocerebral mucormycosis: pathways of spread. Eur Arch Oto-Rhino-Laryngol 262(11):932–938 Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP (2012) Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 54(suppl_1):S55–60 Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, Barac A, Abdollahi A, Khodavaisy S (2021) Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses 64(10):1238–1252. https://doi.org/10.1111/myc.13334 Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H, Chaker A et al (2010) Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx 37(3):322–328 Hargrove RN, Wesley RE, Klippenstein KA, Fleming JC, Haik BG (2006) Indications for orbital exenteration in mucormycosis. Ophthal Plast Reconstr Surg 22(4):286–291 Anaissie EJ, Shikhani AH (1985) Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope 95(9 Pt 1):1107–1113 Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, Rendón-Ramírez EJ, Ayala-Cortés AS, Fraga-Hernández ML et al (2014) Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014:e562610 Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19(12):e405–e421 Pagano L, Valentini CG, Posteraro B, Girmenia C, Ossi C, Pan A et al (2009) Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother Florence Italy 21(3):322–329 Ibrahim AS, Gebremariam T, Husseiny MI, Stevens DA, Fu Y, Edwards JE et al (2008) Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 52(4):1573–1576 Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis Off Publ Infect Dis Soc Am 44(10):1289–1297 Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP (2018) Therapy of mucormycosis. J Fungi 4(3):90 Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE, Spellberg B (2009) Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 53(2):772–775 Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR et al (2012) Invasive mold infections following combat-related injuries. Clin Infect Dis Off Publ Infect Dis Soc Am 55(11):1441–1449 Rodriguez CJ, Tribble DR, Malone DL, Murray CK, Jessie EM, Khan M et al (2018) Treatment of suspected invasive fungal infection in war wounds. Mil Med 183(suppl_2):142–6 Rn H, Re W, Ka K, Jc F, Bg H (2006) Indications for orbital exenteration in mucormycosis. Ophthal Plast Reconstr Surg 22(4):286–291 Hoenigl M, Gangneux J-P, Segal E, Alanio A, Chakrabarti A, Chen SC-A, et al (2018) Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses 61(11):885–894 Guinea J, Escribano P, Vena A, Muñoz P, Martínez-Jiménez M del C, Padilla B et al (2017) Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates. PLOS ONE 12(6):e0179136